Granisetron Lek

Granisetron Lek is a prescription medication that contains the active ingredient granisetron, a selective 5‑HT3 receptor antagonist administered intravenously. It is marketed in the European Union and is used as an antiemetic to help prevent nausea and vomiting associated with chemotherapy and postoperative settings. The product does not have a listed strength or dosage form beyond its intravenous preparation, and it requires a healthcare professional’s prescription.

Granisetron Lek is indicated for the prevention of nausea and vomiting in specific clinical situations.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients. - Prevention of postoperative nausea and vomiting (PONV) after surgical procedures. - Use as part of a multimodal antiemetic regimen when high emetogenic risk is anticipated. - Administration in settings where rapid onset of antiemetic effect is required, such as during infusion of cytotoxic agents. - Intravenous dosing allows for controlled plasma concentrations during short‑term antiemetic therapy. - May be used in combination with corticosteroids or NK‑1 antagonists to enhance anti‑nausea efficacy.

Granisetron Lek can cause a range of adverse effects, which are generally categorized as common or serious based on frequency and clinical significance.

Common: - Headache - Constipation or mild abdominal discomfort - Dizziness or light‑headedness - Transient flushing or warmth sensation - Dry mouth or mild taste alteration - Transient visual disturbances such as blurred vision

Serious: - Severe allergic reaction (anaphylaxis) with rash, swelling, or difficulty breathing - Cardiac arrhythmias, including QT interval prolongation - Persistent severe constipation leading to bowel obstruction - Elevated liver enzymes indicating hepatic stress - Seizure activity in patients with pre‑existing neurological disorders - Hypotension or cardiovascular collapse in susceptible individuals - Most patients tolerate the medication well, but monitoring is advised.

When prescribing Granisetron Lek, clinicians should consider several precautionary measures to ensure safe use.

- Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists. - Evaluate cardiac risk, especially in patients with known QT prolongation or electrolyte disturbances. - Use caution in individuals with hepatic impairment; dose adjustment may be required. - Monitor for signs of constipation, particularly in patients with gastrointestinal motility disorders. - Consider potential interactions with other antiemetics or serotonergic agents. - Review pregnancy and lactation status, as safety data are limited.

Granisetron Lek may interact with other medications, and certain combinations should be avoided or used with caution.

Avoid: - Concurrent use with other 5‑HT3 antagonists, as additive effects increase risk of cardiac arrhythmias. - Combination with potent CYP3A4 inducers that may reduce granisetron plasma levels. - Avoid simultaneous infusion with high-dose dexamethasone that may mask granisetron efficacy.

Use with caution: - Co‑administration with drugs that prolong QT interval (e.g., certain antiarrhythmics, antipsychotics). - Use alongside serotonergic agents such as SSRIs or tramadol, which may increase serotonin syndrome risk. - Concomitant use with opioids that have emetogenic potential, requiring close monitoring. - Caution when combined with other antiemetics that have overlapping mechanisms, such as metoclopramide, to prevent excessive serotonin blockade.